UnitedHealth Group Inc's (NYSE:UNH) recent nosedive wasn't just a chart pattern — it was a conviction breaker. Tom Hulick, CEO of Strategy Asset Managers, didn't wait for a rebound. He dumped the stock, citing "a deterioration in fundamentals" in exclusive insights shared with Benizinga over email. UnitedHealth’s stock is down over 42% year-to-date, over 31% down in the past month alone. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — this is your last chance to become an investor for $0.80 per share. Asset Manager Walks Away From UNH Stock The asset manager's exit from UnitedHealth stock followed a string of gut punches for UnitedHealth: an unexpected CEO resignation, fiscal 2025 guidance withdrawal, and what Hulick called "a rare earnings miss and downward revisions to EPS." But the real red flag? A company that always looked forward suddenly stopped doing so. "When a perennial compounder stops providing forward guidance and leadership turnover coincides with performance slippage, it's a signal to pay attention." The Storm Brewing In Medicare Advantage And Hulick's attention is now on a storm brewing in Medicare Advantage. Once UnitedHealth's profit engine, it's now showing signs of burnout. "Rising utilization, tighter reimbursement, and structural adjustments tied to the CMS risk model transition" have created a perfect storm, Hulick said, adding that "margin compression at a scale that can't be resolved with typical cost controls" could lead to slower growth or even retrenchment. The broader picture isn't much rosier for the managed care sector. With regulators circling and medical loss ratios climbing, Hulick says the core business model is losing its shine. "The upside appears capped relative to prior cycles," he said, noting a shift in the defensive-growth balance that "is not necessarily in favor of the incumbents." See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000. Going Long On Science, Instead So where is the $700 million manager putting its chips? Hulick is going long on science. "We're investing in innovation-driven segments that offer idiosyncratic upside and aren't tethered to reimbursement dynamics." That includes early-stage biotech, gene editing, and longevity plays – plus global insurance firms like Arthur J. Gallagher & Co. (NYSE:AJG), which Hulick says have "demonstrated durable growth, pricing power, and operate in areas less exposed to the volatility we're seeing in U.S. health insurance." Story Continues UNH may be the canary in the managed care coal mine. While Hulick sees "rising costs, regulatory friction, and deteriorating visibility" across the sector, he singles out UnitedHealth as "uniquely exposed" given its size, complexity, and "integration challenges-especially with Optum." The firm has exited UnitedHealth across three equity strategies but is holding onto bonds maturing in 2026 – one place where Hulick still sees strength. "The A+ rating and balance sheet strength remain intact." But in equities, the message is clear: "The focus now is on innovation, not incumbency." Read Next: Hasbro, MGM, and Skechers trust this AI marketing firm — Invest before it's too late. Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share! Image: Shutterstock Send To MSN: Send to MSN UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article EXCLUSIVE: UnitedHealth Gets Dumped, Why This Asset Manager Says Insurer Is No Longer A Safe Bet originally appeared on Benzinga.com View Comments
EXCLUSIVE: UnitedHealth Gets Dumped, Why This Asset Manager Says Insurer Is No Longer A Safe Bet
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...